Introduction
============

Lithium remains an imperative drug in the long term therapy of bipolar affective disorders. It is also a proven prophylactic agent against relapses or recurrences of abnormal mood episodes in unipolar depression, hypomania and mania \[[@B1],[@B2]\]. It has also been shown to reduce suicidal risk and short term mortality \[[@B3]\].

Despite its proven efficaciousness, its use is associated with a myriad of clinical shortcomings. These include: a narrow therapeutic window hence necessitating regular monitoring of therapeutic concentrations, cardiac toxicity, renal tubular dysfunction and endocrinopathies like thyroid abnormalities, hyperparathyroidism, transient hyperglycemia and nephrogenic diabetes insipidus \[[@B2],[@B4]-[@B7]\]. This review will focus mainly on the effects of lithium on the normal physiological functioning of the thyroid gland and the frequently reported thyroid abnormalities associated with lithium therapy.

General pharmacological features of lithium
-------------------------------------------

Lithium is an alkali metal which is available mainly as lithium carbonate and citrate in immediate- and sustained-release preparations. It reaches peak plasma concentrations in 1--2 and 4--5 hours for the immediate and sustained release formulations respectively with an elimination half life of 18--36 hours. Its excretion is primarily via the kidneys and this renal clearance decreases with increasing age \[[@B8]\].

The precise mechanisms by which lithium exerts its mood stabilising effects are still not very apparent. Its neurotropic effects are partially explained by the inhibitory effect on the N-methyl D-aspartate receptor that mediates cellular calcium influx and the suppression of activation of pro-apoptotic calcium dependent signalling pathways \[[@B9]\]. Lithium also alters release of neurotransmitters and lessens glutaminergic activity \[[@B10]\].

Effects of lithium on the physiology of the thyroid gland
---------------------------------------------------------

Multiple effects of lithium on the physiology of the thyroid gland have been extensively studied. Lithium has been shown to be highly concentrated in thyroid cells. In-vivo and vitro studies in rats have shown that lithium reduces the uptake of radioiodine into rat thyroid and salivary glands. In humans, lithium administration may result in either reduced or increased thyroidal radioiodine uptake. Several mechanisms are thought to explain this dual effect among humans. Low thyroid iodine uptake could be due to lithium induced iodide retention and competition for the iodide transport within the thyroid gland. An increase in the uptake could be mediated by the increased secretion of thyroid stimulating hormone (TSH) following lithium induced hypothyroidism \[[@B11]\].

Another key effect of lithium on thyroid gland functioning occurs at the level of hormone synthesis and release. Lithium inhibits synthesis and release of thyroid hormones. This inhibitory effect is due to the alteration in the tubulin polymerisation and inhibition of the action of TSH on cyclic adenosine mono phosphate (c-AMP). Lithium also alters the structure of thyroglobulin thereby affecting protein conformation and function with subsequent iodotyrosine coupling defects. Lithium administration is associated with reduced hepatic deiodination and clearance of free thyroxine (T~4~). The latter induces a decrease in the activity of type I 5' de-iodinase enzyme \[[@B11],[@B12]\].

Thyroid abnormalities due to lithium therapy
--------------------------------------------

### Goitre

The initial inhibition of thyroid hormone synthesis and release by lithium results into increased TSH concentrations leading to thyroid enlargement. Other mechanisms proposed to explain thyrocyte proliferation among patients on lithium therapy are activation of the pro-proliferative tyrosine kinase and Wnt/beta-catenin signalling pathways \[[@B12]-[@B14]\].

Goitre is the most common clinical finding noted among patients on lithium therapy. It occurs as a diffuse and non tender neck swelling. Varying prevalence of goitre among treated patients has been reported in the several published studies. This is explained by the differences in iodine content in the geographical study settings, duration of lithium use and diagnostic study techniques used \[[@B12]\].

In one early study by Schou et al. among 330 manic-depressive patients on lithium therapy, clinically detected goitre was noted among 12 patients, giving a prevalence of 3.6%. The calculated annual incidence was 4% compared to 1% incidence in a geographically comparable healthy general population \[[@B15]\]. In another survey by Bocchetta et al. among 150 outpatients on long term lithium therapy, the prevalence of a visible and / clinically palpable goitre was 51% \[[@B16]\]. This prevalence reduced with subsequent follow up \[[@B17],[@B18]\].

Thyroid ultrasonography has been demonstrated to be a simple, cheap and sensitive method for screening for goitre and thyroid abnormalities among patients on lithium therapy \[[@B19]\]. In one cross sectional study to determine the thyroid size and prevalence of goitre among 96 treated patients with affective disorders in Germany, goitre was reported among 53 (55%) patients on lithium therapy and 19 (20%) controls (p = 0.003) \[[@B20]\]. In this study, screening using thyroid ultrasonography identified more patients with goitre compared to clinical palpation (N = 53 Vs 19, p \< 0.01 compared to N = 24 Vs 12, p \< 0.001 respectively).

Other cross sectional studies have reported similar findings of higher frequency of goitre of 50% \[[@B21]\]-59% \[[@B22]\] among lithium treated patients.

The approach to management of lithium induced goitre is comparable to that among healthy population. However, levothyroxine replacement therapy is preferred more among patients with significant thyroid enlargement and accompanying compressive symptoms \[[@B12]\].

### Hypothyroidism and subclinical hypothyroidism

Hypothyroidism and subclinical hypothyroidism with/without concomitant goitre is also very prevalent among patients on lithium therapy in varying reported frequencies ranging from 0% to 52% \[[@B16],[@B22]-[@B27]\]. Similarly, disparities in prevalence can be explained by different study definitions, iodine intake and baseline thyroid autoimmunity among study subjects \[[@B28]\]. The average duration of lithium administration prior to the diagnosis of hypothyroidism is about 18 months, although it can occur within the first few months \[[@B29]\].

Bocchetta et al. in a study among 150 ambulatory Sardinian patients on lithium therapy, no cases of clinical hypothyroidism were documented. Subclinical hypothyroidism was noted in 19% of the patients. Among lithium treated patients with positive thyroid antibodies, the prevalence of subclinical hypothyroidism increased to 53%. The prevalence of specific antithyroid antibodies was positively correlated with age and duration of lithium treatment, and was higher among women \[[@B16]\].

In another cross sectional study by Kirov et al. among 115 males and 159 females with affective disorders on long term lithium therapy in the UK, the prevalence of hypothyroidism was 10.3%. The prevalence was higher among female patients compared to males (n = 27, 17% Vs n = 4, 3.5% respectively) \[[@B30]\]. A retrospective study of 718 patients on lithium therapy by Johnson and Eagles reported a comparable prevalence of clinical hypothyroidism of 10.4% especially among female gender (14% Vs 4.5%). The calculated annual incidence of hypothyroidism in this study was 2.17% and 0.68% among women and men respectively \[[@B26]\], relatively higher than the reported figures among the community in the Whickham survey \[[@B31]\].

The aetiology of lithium associated hypothyroidism and subclinical hypothyroidism is primarily related to inhibition of synthesis and release of thyroid hormones \[[@B12]\]. Other studies have demonstrated a transient lithium induced increase in titres of thyroid auto-antibodies (thyroid peroxidase auto-antibodies) present prior to lithium administration. No lithium induced production of thyroid auto-antibodies independently is thought to occur \[[@B32],[@B33]\]. However, some studies have reported contrasting results in relation to lithium inducing an increase in the titres of thyroid auto-antibodies. In a cross sectional study by Baethge et al. among 100 adults with major affective disorders matched with 100 age-and sex matched controls with no history of an axis I psychiatric diagnosis, there was no significant difference in the prevalence of auto-antibodies against thyroid peroxidase and thyroglobulin between the patients and the age- and sex matched healthy controls (0.07% Vs 0.11% and 0.08% Vs 0.15% respectively). TSH receptor auto-antibodies were not found in either group \[[@B34]\].

The risk of developing lithium induced hypothyroidism has been shown to be significantly higher among females, with increasing age (\>50 years), presence of family history of thyroid disease and thyroid auto-antibodies \[[@B28],[@B29],[@B35]\]. Due to this high frequency of hypothyroidism, it is clinically plausible to assess the thyroid function status, thyroid size and presence of thyroid auto-antibodies in all patients prior to initiation of lithium therapy and later annually. More frequent assessment of thyroid function tests (at least every 3--4 months) among middle aged females (\>50 years) who are thyroid auto-antibody positive with family history of thyroid disease is recommended \[[@B29],[@B36]\]. Levothyroxine replacement therapy concurrently with lithium administration especially in the presence of clinically overt hypothyroidism, significantly enlarged thyroid glands, subclinical hypothyroidism and in rapidly cycling or treatment resistant cases is recommended in the management of lithium induced hypothyroidism \[[@B29]\].

### Hyperthyroidism/thyrotoxicosis

Hyperthyroidism may occur with long term lithium treatment though to a less extent compared to goitre and hypothyroidism \[[@B23],[@B30],[@B37]-[@B40]\]. In the retrospective study by Kirov among 209 patients with affective disorders on long term lithium therapy, post treatment thyrotoxicosis was noted among 2 patients (1 male and 1 female) \[[@B23]\]. Thyrotoxicosis however was noted to occur earlier in the course of treatment and at a younger age in the female patient compared to the male patient (6 years Vs 9 years later and 42 years Vs 50 years respectively).

In another cross sectional study, 2 (1.8%) of 111 men who had a mean duration of 80 months of lithium therapy developed thyrotoxicosis, giving an incidence rate of 2.7/1000 survivor years. Only 6 (3.9%) of 152 women with a mean duration of 73.3 months of lithium therapy developed thyrotoxicosis, giving an incidence rate of 6.4/1000 survivor years \[[@B24]\]. In the prospective study by the same research group among 33 women, only 1 woman developed hyperthyroidism over the 146 person-years of follow up \[[@B24]\]. Bocchetta et al. noted only 1 case of hyperthyroidism among 150 patients on long term lithium therapy during a 15 year follow up equivalent to 976 patient-years, suggesting that lithium induced hyperthyroidism is extremely rare \[[@B40]\].

Lithium induced hyperthyroidism is mainly characterised by a transient and painless thyroiditis. Some published reports have also shown that lithium is associated with granulomatous thyroiditis, lymphocytic thyroiditis or non-specific thyroiditis \[[@B41],[@B42]\]. In one single centre experience among 23 patients with lithium induced thyrotoxicosis with a median duration of 6 years of lithium therapy (0.6-25 years), transient thyrotoxicosis with a painless thyroiditis was noted among 9 (23%) patients \[[@B42]\].

This transient and painless thyroiditis is thought to be due to a possible direct toxic effect of lithium on the thyroid gland \[[@B41]\]. Another mechanism proposed in the pathogenesis of lithium induced hyperthyroidism/thyrotoxicosis is related to autoimmunity and auto-antibody production. In a study by Wilson et al., 20% of lithium treated patients had thyroid auto-antibodies compared to 7.5% not on lithium treatment. Lithium treatment in this study was shown to increase B cell activity and decreased ratios of suppressor to cytotoxic T cells \[[@B43]\]. This demonstrates that lithium induces thyroid autoimmunity among susceptible individuals.

Patients with lithium induced hyperthyroidism are best treated with anti thyroid drugs like carbimazole with/without steroids. Radioiodine or thyroidectomy should be reserved for patients with lithium induced Graves' disease especially in cases of poor compliance to the anti thyroid drugs. In cases of a toxic nodular goitre with/without compressive symptoms, a thyroidectomy is indicated.

In cases of lithium induced thyroiditis, ablative radioiodine is not indicated because of its poor uptake. Conservative management with regular follow up is recommended in such cases since majority of the patients develop hypothyroidism subsequently \[[@B42]\].

Conclusions
===========

Lithium being an effective and pivotal drug in the management of affective disorders, concomitant thyroid dysfunction remains a pertinent clinical subject to address. Significant proportions of patients treated with lithium develop clinically or radiologically confirmed goitre and hypothyroidism. Lithium increases the risk of thyroid autoimmunity in susceptible individuals. Lithium induced hyperthyroidism is infrequent.

Baseline and regular assessment of thyroid function tests (TSH, free T4); thyroid size using thyroid ultrasonography and measurement of titres of auto-antibodies against thyroid peroxidase is recommended among patients prior and during lithium therapy.
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